Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.
BACKGROUND: Evidence on associations between self-reported diabetes mellitus, diabetes duration, age at diabetes diagnosis, insulin treatment, and risk of biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), independent of general and abdominal obesity is scarce. PATIENTS AND METHODS: We c...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826271907517825024 |
|---|---|
| author | Schlesinger, S Aleksandrova, K Pischon, T Jenab, M Fedirko, V Trepo, E Overvad, K Roswall, N Tjønneland, A Boutron-Ruault, M Fagherazzi, G Racine, A Kaaks, R Grote, V Boeing, H Trichopoulou, A Pantzalis, M Kritikou, M Mattiello, A Sieri, S Sacerdote, C Palli, D Tumino, R Peeters, P Bueno-de-Mesquita, H |
| author_facet | Schlesinger, S Aleksandrova, K Pischon, T Jenab, M Fedirko, V Trepo, E Overvad, K Roswall, N Tjønneland, A Boutron-Ruault, M Fagherazzi, G Racine, A Kaaks, R Grote, V Boeing, H Trichopoulou, A Pantzalis, M Kritikou, M Mattiello, A Sieri, S Sacerdote, C Palli, D Tumino, R Peeters, P Bueno-de-Mesquita, H |
| author_sort | Schlesinger, S |
| collection | OXFORD |
| description | BACKGROUND: Evidence on associations between self-reported diabetes mellitus, diabetes duration, age at diabetes diagnosis, insulin treatment, and risk of biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), independent of general and abdominal obesity is scarce. PATIENTS AND METHODS: We conducted a prospective analysis in the EPIC-cohort study among 363 426 participants with self-reported diabetes data. Multivariable adjusted relative risks and 95% confidence intervals were estimated from Cox regression models. In a nested case-control subset, analyses were carried out in HCV/HBV-negative individuals. RESULTS: During 8.5 years of follow-up, 204 BTC cases [including 75 gallbladder cancer (GBC) cases], and 176 HCC cases were identified. Independent of body mass index and waist-to-height ratio diabetes status was associated with higher risk of BTC and HCC [1.77 (1.00-3.13) and 2.17 (1.36-3.47)]. For BTC, the risk seemed to be higher in participants with shorter diabetes duration and those not treated with insulin. Regarding cancer subsites, diabetes was only associated with GBC [2.72 (1.17-6.31)]. The risk for HCC was particularly higher in participants treated with insulin. The results were not appreciably different in HCV/HBV-negative individuals. CONCLUSION(S): This study supports the hypothesis that diabetes is a risk factor for BTC (particularly GBC) and HCC. Further research is required to establish whether diabetes treatment or duration is associated with these cancers. |
| first_indexed | 2024-03-06T22:04:08Z |
| format | Journal article |
| id | oxford-uuid:4f951e4f-0f35-41f0-bb68-6a5251860367 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:04:08Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:4f951e4f-0f35-41f0-bb68-6a52518603672022-03-26T16:08:05ZDiabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4f951e4f-0f35-41f0-bb68-6a5251860367EnglishSymplectic Elements at Oxford2013Schlesinger, SAleksandrova, KPischon, TJenab, MFedirko, VTrepo, EOvervad, KRoswall, NTjønneland, ABoutron-Ruault, MFagherazzi, GRacine, AKaaks, RGrote, VBoeing, HTrichopoulou, APantzalis, MKritikou, MMattiello, ASieri, SSacerdote, CPalli, DTumino, RPeeters, PBueno-de-Mesquita, HBACKGROUND: Evidence on associations between self-reported diabetes mellitus, diabetes duration, age at diabetes diagnosis, insulin treatment, and risk of biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), independent of general and abdominal obesity is scarce. PATIENTS AND METHODS: We conducted a prospective analysis in the EPIC-cohort study among 363 426 participants with self-reported diabetes data. Multivariable adjusted relative risks and 95% confidence intervals were estimated from Cox regression models. In a nested case-control subset, analyses were carried out in HCV/HBV-negative individuals. RESULTS: During 8.5 years of follow-up, 204 BTC cases [including 75 gallbladder cancer (GBC) cases], and 176 HCC cases were identified. Independent of body mass index and waist-to-height ratio diabetes status was associated with higher risk of BTC and HCC [1.77 (1.00-3.13) and 2.17 (1.36-3.47)]. For BTC, the risk seemed to be higher in participants with shorter diabetes duration and those not treated with insulin. Regarding cancer subsites, diabetes was only associated with GBC [2.72 (1.17-6.31)]. The risk for HCC was particularly higher in participants treated with insulin. The results were not appreciably different in HCV/HBV-negative individuals. CONCLUSION(S): This study supports the hypothesis that diabetes is a risk factor for BTC (particularly GBC) and HCC. Further research is required to establish whether diabetes treatment or duration is associated with these cancers. |
| spellingShingle | Schlesinger, S Aleksandrova, K Pischon, T Jenab, M Fedirko, V Trepo, E Overvad, K Roswall, N Tjønneland, A Boutron-Ruault, M Fagherazzi, G Racine, A Kaaks, R Grote, V Boeing, H Trichopoulou, A Pantzalis, M Kritikou, M Mattiello, A Sieri, S Sacerdote, C Palli, D Tumino, R Peeters, P Bueno-de-Mesquita, H Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title_full | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title_fullStr | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title_full_unstemmed | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title_short | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. |
| title_sort | diabetes mellitus insulin treatment diabetes duration and risk of biliary tract cancer and hepatocellular carcinoma in a european cohort |
| work_keys_str_mv | AT schlesingers diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT aleksandrovak diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT pischont diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT jenabm diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT fedirkov diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT trepoe diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT overvadk diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT roswalln diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT tjønnelanda diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT boutronruaultm diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT fagherazzig diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT racinea diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT kaaksr diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT grotev diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT boeingh diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT trichopouloua diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT pantzalism diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT kritikoum diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT mattielloa diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT sieris diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT sacerdotec diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT pallid diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT tuminor diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT peetersp diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort AT buenodemesquitah diabetesmellitusinsulintreatmentdiabetesdurationandriskofbiliarytractcancerandhepatocellularcarcinomainaeuropeancohort |